NASDAQ:ITOS iTeos Therapeutics Q3 2023 Earnings Report $10.15 0.00 (0.00%) As of 08/29/2025 ProfileEarnings HistoryForecast iTeos Therapeutics EPS ResultsActual EPS-$0.90Consensus EPS -$1.20Beat/MissBeat by +$0.30One Year Ago EPSN/AiTeos Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AiTeos Therapeutics Announcement DetailsQuarterQ3 2023Date11/7/2023TimeN/AConference Call DateTuesday, November 7, 2023Conference Call Time7:00AM ETUpcoming EarningsiTeos Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) iTeos Therapeutics Earnings HeadlinesiTeos Therapeutics (NASDAQ:ITOS) Upgraded to Sell at Wall Street ZenAugust 31, 2025 | americanbankingnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of ShareholdersAugust 20, 2025 | prnewswire.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.September 4 at 2:00 AM | SmartAsset (Ad)ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOSAugust 19, 2025 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of ShareholdersJuly 21, 2025 | globenewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.July 21, 2025 | prnewswire.comSee More iTeos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iTeos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iTeos Therapeutics and other key companies, straight to your email. Email Address About iTeos TherapeuticsiTeos Therapeutics (NASDAQ:ITOS) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies. The company’s research centers on targeting key components of the tumor microenvironment to restore and enhance anti-tumor immune responses. Its core therapeutic approach involves small molecules and monoclonal antibodies designed to inhibit immunosuppressive pathways that allow cancers to evade immune surveillance. The company’s pipeline includes EOS-850, an orally administered adenosine A2A receptor antagonist, and EOS-448, a first-in-class anti-TIGIT monoclonal antibody. EOS-850 is being evaluated as both a monotherapy and in combination with established immune checkpoint inhibitors in multiple tumor types. EOS-448 is under investigation for its potential to block the TIGIT pathway, thereby reinvigorating T-cell activity against solid tumors. iTeos also continues to advance additional preclinical programs targeting adenosine generation and TGF-β signaling. Founded in 2015 as a spin-out from leading academic research institutions, iTeos Therapeutics completed its initial public offering on the NASDAQ in 2019. The company is headquartered in Cambridge, Massachusetts, with research and development laboratories in Gosselies, Belgium, supporting both early-stage discovery and global clinical trial activities. This transatlantic footprint enables iTeos to collaborate with academic centers and industry partners across North America and Europe. iTeos is led by a management team with deep expertise in oncology drug development and regulatory strategy. The leadership group has navigated multiple clinical milestones, forging partnerships and securing funding to advance its immuno-modulatory candidates through regulatory interactions and patient trials. With a focus on translating scientific insights into differentiated therapies, the company aims to address high-unmet medical needs for patients with advanced cancers.Written by Jeffrey Neal JohnsonView iTeos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ambarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised Guidance Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
